A meta-analysis of interferon-β in the secondary progressive multiple sclerosis

National Medical Journal of China

Volumn 89, Issue 21, 2009, Pages 1484-1489

  Fan, Xin ^a   Yang, Li ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Interferon ; Meta analysis; Multiple sclerosis

Indexed keywords

BETA INTERFERON;

ARTICLE; FEMALE; HUMAN; MALE; META ANALYSIS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

FEMALE; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME;

EID: 84871276469     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.21.014     Document Type: Article

References (27)

1. Weishenker BG, Bass B, Rice GP, et al. The natural history of multiple Sclerosis: a geographically based study. I. Cliniacal course and disability. Brain, 1989, 112: 133-146.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trals If New Agents in Multiple Sclerosis. Neurology, 1996, 46: 907-911.
3. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology. Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology, 2002, 58: 169-178.
4. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 1993, 43: 655-661.
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferonbeta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol, 1996, 39: 285-294.
6. Patty DW, Li DK. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 1993, 43: 662-667.
7. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology, 1995, 45: 1277-1285.
8. Rio J, Tintore M, Nos C, et al. Interferon beta in secondary progressive multiple sclerosis: daliy clinical practice. J Neurol, 2007, 254: 849-853.
9. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Nerology, 2004, 63: 1779-1787.
10. McCormack PL, Scott LJ. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis. Biodrugs, 2004, 18: 343-347.
11. Clanet M, Radue EW, Leappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology, 2002, 59: 1507-1517.
12. Freeman JA, Thompson AJ, Fitzpatrich R, et al. Interferon-beta 1b in treatment of secondary progressive MS: impact on quality of life. Neurology, 2001, 57: 1870-1875.
13. European Study Group on interferon 1b in secondary progressive MS. placebo-controlled multicentre randomized trial of interferon-1b in treatment of secondary progressive multiple sclerosis. Lancet, 1998, 352: 1491-1497.
14. Panitch H, Miller A, Paty D, et al. Interferon beta-lb in secondary progressive MS. results from a 3-year controlled study. Neurology, 2004, 63: 1788-1795.
15. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS clinical results. Neurology, 2001, 56: 1496-1504.
16. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomized, double blind, placebo controlled, phase EI study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry, 2004, 75: 706-710.
17. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology, 2002, 59: 679-687.
18. Patti F, L'Episcopo MR, Cataldi ML, et al. Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study. Acta Neurol Scand, 1999, 100: 283-289.
19. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain, 1997, 120: 865-916.
20. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple Sclerosis. N Engl J Med, 2000, 343: 938-952.
21. Filippini G, Munari L, Incorvaia B. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet, 2003, 361: 545-552.
22. Whitaker JN, McFarland HF, Rudge P, et al. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler, 1995, 1: 37-47
23. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology, 2002, 59: 679-687.
24. PRISMS Study Croup and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferonbeta-1a in relapsing MS. Neurology, 2001, 56: 1628-1636.
25. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS. A combined analysis of the two trials. Neurology, 2004, 63: 1779-1787.
26. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, 2001, 357: 1576-1582.
27. Viliar J, Carroli G, Belizan JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet, 1995, 345: 772-776.